ICU Medical, Inc. (NASDAQ:ICUI) Receives $175.67 Consensus PT from Brokerages

Shares of ICU Medical, Inc. (NASDAQ:ICUI) have received a consensus rating of “Moderate Buy” from the five ratings firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $175.6667.

A number of brokerages have weighed in on ICUI. Weiss Ratings reissued a “sell (d-)” rating on shares of ICU Medical in a report on Thursday, January 22nd. Wall Street Zen cut shares of ICU Medical from a “buy” rating to a “hold” rating in a report on Saturday. Piper Sandler lifted their target price on ICU Medical from $153.00 to $172.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Finally, KeyCorp upped their price objective on ICU Medical from $173.00 to $175.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th.

ICU Medical Stock Up 3.0%

ICUI opened at $154.16 on Friday. ICU Medical has a 52 week low of $107.00 and a 52 week high of $165.17. The company has a quick ratio of 1.19, a current ratio of 2.45 and a debt-to-equity ratio of 0.62. The business has a 50 day moving average price of $148.59 and a two-hundred day moving average price of $134.50. The company has a market cap of $3.81 billion, a PE ratio of -497.27 and a beta of 0.79.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $2.03 EPS for the quarter, beating the consensus estimate of $1.43 by $0.60. The firm had revenue of $533.30 million during the quarter, compared to analysts’ expectations of $511.46 million. ICU Medical had a negative net margin of 0.32% and a positive return on equity of 7.71%. The business’s revenue for the quarter was down 8.9% compared to the same quarter last year. During the same quarter last year, the business earned $1.59 earnings per share. As a group, research analysts anticipate that ICU Medical will post 4.11 EPS for the current year.

Insider Activity

In other news, VP Virginia Ruth Sanzone sold 930 shares of the stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $142.34, for a total transaction of $132,376.20. Following the transaction, the vice president owned 5,456 shares in the company, valued at $776,607.04. This represents a 14.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Elisha W. Finney sold 1,285 shares of the company’s stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $140.42, for a total value of $180,439.70. Following the sale, the director owned 3,995 shares of the company’s stock, valued at approximately $560,977.90. This trade represents a 24.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Inscription Capital LLC grew its holdings in shares of ICU Medical by 407.9% during the third quarter. Inscription Capital LLC now owns 8,365 shares of the medical instruments supplier’s stock worth $1,003,000 after purchasing an additional 6,718 shares in the last quarter. Federated Hermes Inc. boosted its position in ICU Medical by 56.5% during the third quarter. Federated Hermes Inc. now owns 290,292 shares of the medical instruments supplier’s stock valued at $34,823,000 after buying an additional 104,798 shares during the period. Emerald Mutual Fund Advisers Trust purchased a new stake in ICU Medical during the 3rd quarter valued at about $1,096,000. Simon Quick Advisors LLC purchased a new stake in shares of ICU Medical during the second quarter valued at approximately $275,000. Finally, AlphaQuest LLC boosted its position in ICU Medical by 3,058.3% during the 2nd quarter. AlphaQuest LLC now owns 1,516 shares of the medical instruments supplier’s stock valued at $200,000 after buying an additional 1,468 shares during the period. 96.10% of the stock is owned by institutional investors.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.